14. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP.Gastroen- terology. 2007;132:2131-2157. 15. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor ago- nists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. 16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices.Br J Surg. 1973;60:646-649. 17. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate.Ann Intern Med. 2009;150:604-612. 18. FDA Guidance for Industry. Pharmacokinetics in patients with impaired hepatic function - trial design, data analysis, and impact on dosing and labelling. 2003. https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072123. pdf. Accessed June 8, 2017. 19. EMA, Committee for Medicinal Products for Human Use CPMP. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function (CHMP/EWP/2339/02). 2005. http://www.ema.europa.eu/docs/en_ GB/document_library/Scientific_guideline/2009/09/WC500003122. pdf. Accessed June 8, 2017. 20. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA. 2000;284: 3043-3045.